Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Analyst picks & changes

Analyst picks & changes

Company Bank Analyst Coverage Opinion Wk chg 9/21 cls
BioCryst (BCRX) Caris Douglas Chow Downgrade Average (from above average) -32% $7.98
ThinkEquity Chris Holterhoff Downgrade Accumulate (from buy)
Chow lowered his target to $9.50 from $13 after BCRX's peramivir, a viral neuraminidase inhibitor, failed to significantly reduce median time to alleviation of symptoms vs. placebo, the primary endpoint, in

Read the full 636 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers